The present disclosure relates to a strain of Lactobacillus sakei HEM224 (KCTC14065BP) and a composition for treating, preventing or alleviating inflammation or asthma, comprising the strain.

A strain of Lactobacillus sakei HEM224 (KCTC14065BP) according to an embodiment of the present disclosure inhibits the production of pro-inflammatory factors or inflammatory factors, and exhibits an effect of treating asthma in an asthma animal model. Therefore, the strain can be applied to pharmaceutical compositions, food compositions, health functional food compositions and feed compositions for treating, preventing or alleviating inflammation or asthma.

The invention relates to a feed additive comprising at least one nutrient, which non-nutrient is incorporated in a matrix, the entirety being encapsulated by a coating comprising at least a plant material whose saponification number is greater than 180.

The invention also deals with a method for preparing a feed additive.

Finally, the invention also relates to the use of the feed additive to improve the zootechnical performance of a ruminant.

The invention relates to a feed additive comprising at least one nutrient, which non-nutrient is incorporated in a matrix, the entirety being encapsulated by a coating comprising at least a plant material whose saponification number is greater than 180.

The invention also deals with a method for preparing a feed additive.

Finally, the invention also relates to the use of the feed additive to improve the zootechnical performance of a ruminant.

The invention concerns the use of fucosylated non-digestible human milk oligosaccharide, or a composition comprising a fucosylated non-digestible human milk oligosaccharide, for use in improving immune fitness in a human subject, wherein the human subject is male.

The invention concerns the use of fucosylated non-digestible human milk oligosaccharide, or a composition comprising a fucosylated non-digestible human milk oligosaccharide, for use in improving immune fitness in a human subject, wherein the human subject is male.

Disclosed are nutritional compositions including human milk oligosaccharides and nucleotides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

Disclosed are nutritional compositions including human milk oligosaccharides and nucleotides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

The present disclosure relates to a pharmaceutical composition for preventing, treating or ameliorating inflammatory bowel disease, containing, as an active ingredient, a specific solvent fraction obtained from Saururus chinensis; and a preparation method therefor.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.